Robert Lookstein

Dr. Robert A. Lookstein, MD, MHCDL, FSIR, FAHA, FSVM,
A 1995 graduate of the State University of New York Downstate Health Sciences University College of Medicine, Dr. Lookstein honed his skills through a rigorous residency in diagnostic radiology and a fellowship in vascular and interventional radiology at Mount Sinai Hospital. His association with Mount Sinai has been both enduring and impactful, culminating in his current roles as Professor of Radiology and Surgery at the Icahn School of Medicine and Executive Vice Chairman of the Department of Diagnostic, Molecular, and Interventional Radiology for the Mount Sinai Health System .
Beyond his clinical and academic responsibilities, Dr. Lookstein is deeply invested in research that shapes the future of vascular care. He has been instrumental in several pivotal studies, including the VENITE VICI venous stent trial, the SAVAL study on drug-coated stents in lower leg arteries, the PRESERVE registry evaluating the safety and efficacy of Inferior Vena Cava filters, the InPACT AV trial evaluating the role of drug coated balloons for hemodialysis fistula maintenance, the STORM-PE trial evaluating the role of percutaneous thrombectomy for acute pulmonary embolism, and the NHLBI-funded BEST-CLI trial assessing endovascular revascularization for critical limb ischemia .
His leadership extends to the global stage, where he serves as the 2025–2026 President of the Society of Interventional Radiology (SIR). In this capacity, Dr. Lookstein advocates for a longitudinal clinical practice model in interventional radiology, emphasizing the importance of multidisciplinary teamwork and the integration of artificial intelligence to enhance patient outcomes .

Dr. Robert A. Lookstein, MD, MHCDL, FSIR, FAHA, FSVM,
A 1995 graduate of the State University of New York Downstate Health Sciences University College of Medicine, Dr. Lookstein honed his skills through a rigorous residency in diagnostic radiology and a fellowship in vascular and interventional radiology at Mount Sinai Hospital. His association with Mount Sinai has been both enduring and impactful, culminating in his current roles as Professor of Radiology and Surgery at the Icahn School of Medicine and Executive Vice Chairman of the Department of Diagnostic, Molecular, and Interventional Radiology for the Mount Sinai Health System .
Beyond his clinical and academic responsibilities, Dr. Lookstein is deeply invested in research that shapes the future of vascular care. He has been instrumental in several pivotal studies, including the VENITE VICI venous stent trial, the SAVAL study on drug-coated stents in lower leg arteries, the PRESERVE registry evaluating the safety and efficacy of Inferior Vena Cava filters, the InPACT AV trial evaluating the role of drug coated balloons for hemodialysis fistula maintenance, the STORM-PE trial evaluating the role of percutaneous thrombectomy for acute pulmonary embolism, and the NHLBI-funded BEST-CLI trial assessing endovascular revascularization for critical limb ischemia .
His leadership extends to the global stage, where he serves as the 2025–2026 President of the Society of Interventional Radiology (SIR). In this capacity, Dr. Lookstein advocates for a longitudinal clinical practice model in interventional radiology, emphasizing the importance of multidisciplinary teamwork and the integration of artificial intelligence to enhance patient outcomes .

Anahita Dua, MD, MS, MBA, FACS, is a vascular surgeon at Massachusetts General Hospital and an associate professor of Surgery at Harvard Medical School. At Mass General, she is the co-director of the Peripheral Artery Disease Center and Limb Evaluation and Amputation Program (LEAPP), associate director of the Wound Care Center, clinical director of research, and associate director of the Vascular Surgery Clerkship.

She specializes in advanced endovascular (minimally invasive) and traditional (open) limb salvage techniques for treating peripheral arterial disease and critical limb ischemia, diabetic limb disease, aortic disease, carotid disease, thoracic outlet syndrome and venous disease.

Dr. Dua completed her vascular surgery fellowship at Stanford University Hospital and general surgery residency at the Medical College of Wisconsin. She has also completed a master’s degree in trauma sciences, a master’s in business administration in health care management and has a certificate in health economics/outcomes research as well as a certificate in drug and device development from the Massachusetts Institute of Technology. She is board-certified in vascular surgery, general surgery and advanced wound care and management.

Dr. Dua has published over 200 peer reviewed papers and has edited four vascular surgery medical textbooks. She serves on multiple national vascular surgery committees through the Society for Vascular Surgery and other vascular organizations including the South Asian-American Vascular Society and American College of Surgeons. Dr. Dua's NIH Funded lab focuses on anticoagulation and biomarkers that are predictive of thrombosis and hemostasis in patients that have undergone revascularization.

Dr. Elizabeth Genovese is an Assistant Professor of Surgery at the University of Pennsylvania and is the Director of the Penn Advanced Limb Preservation Program at the Hospital of the University of Pennsylvania. Dr. Genovese graduated from the University of Notre Dame, attended medical school at the University of Pittsburgh and completed her Integrated Vascular Surgery Residency at the University of Pittsburgh Medical Center, where she served as Chief Resident. Dr. Genovese specializes in advanced open and complex endovascular treatment of peripheral arterial disease, particularly chronic limb threatening ischemia. She currently serves as the Chair of the SUPRA INGUINAL and INFRA INGUINAL BYPASS VQI modules, and continues to participated in multiple local, regional and national societal committees. Her research focuses on healthcare disparities in peripheral arterial disease detection, treatment and outcomes, along with integration of new technology to streamline treatment algorithms and improve outcomes with complex endovascular therapies for peripheral arterial disease.

Interventional angiologist, Head of Vascular Centre Berlin Alexianer St. Gertrauden-Hospital, Board Member of the German Society of Angiology, personal case load >20.000 cases, academic research primarily endovascular therapy

Dr. Robert A. Lookstein, MD, MHCDL, FSIR, FAHA, FSVM,
A 1995 graduate of the State University of New York Downstate Health Sciences University College of Medicine, Dr. Lookstein honed his skills through a rigorous residency in diagnostic radiology and a fellowship in vascular and interventional radiology at Mount Sinai Hospital. His association with Mount Sinai has been both enduring and impactful, culminating in his current roles as Professor of Radiology and Surgery at the Icahn School of Medicine and Executive Vice Chairman of the Department of Diagnostic, Molecular, and Interventional Radiology for the Mount Sinai Health System .
Beyond his clinical and academic responsibilities, Dr. Lookstein is deeply invested in research that shapes the future of vascular care. He has been instrumental in several pivotal studies, including the VENITE VICI venous stent trial, the SAVAL study on drug-coated stents in lower leg arteries, the PRESERVE registry evaluating the safety and efficacy of Inferior Vena Cava filters, the InPACT AV trial evaluating the role of drug coated balloons for hemodialysis fistula maintenance, the STORM-PE trial evaluating the role of percutaneous thrombectomy for acute pulmonary embolism, and the NHLBI-funded BEST-CLI trial assessing endovascular revascularization for critical limb ischemia .
His leadership extends to the global stage, where he serves as the 2025–2026 President of the Society of Interventional Radiology (SIR). In this capacity, Dr. Lookstein advocates for a longitudinal clinical practice model in interventional radiology, emphasizing the importance of multidisciplinary teamwork and the integration of artificial intelligence to enhance patient outcomes .

Dr. Pradeep K. Nair, an interventional cardiologist, is Vice-Chairman of New Cardiovascular Horizons Conference in New Orleans, LA. He joined the Cardiovascular Institute of the South (CIS) in 2015. A native of Somerset Pennsylvania, he graduated with University Honors from Carnegie Mellon University and earned his medical doctorate at Drexel University College of Medicine. He completed his residency in internal medicine and fellowships in cardiovascular disease and interventional cardiology at the University of Pittsburgh Medical Center Presbyterian Campus where he was recognized with several awards of distinction for his cardiovascular research. He went on to complete a year of an advanced endovascular interventional fellowship under the mentorship of Craig Walker at the CIS in Houma, LA.

Dr. Nair is licensed by the State Board of Medicine in Pennsylvania and Louisiana. He is board certified in internal medicine, cardiovascular disease, interventional cardiology, nuclear cardiology and echocardiography. He currently practices in Houma, Gray and Zachary, Louisiana where he specializes in peripheral arterial/venous disease and interventions. He is a fellow of the American College of Cardiology (ACC) and the Society of Cardiac Angiography and Interventions. He serves Horizon's International Peripheral Group, Board of OEIS, ACC Vascular Disease Section Leadership Council, and CLI Global Society Publication Committee. He has authored multiple peer-reviewed publications, book chapters, and presented and performed Live Endovascular Cases at several cardiovascular meetings. Having a keen clinical research interest of novel interventional devices and therapies, he is dedicated to supporting the advancement of our field.